Magnetic Accumulation of SPIONs under Arterial Flow Conditions: Effect of Serum and Red Blood Cells by Hennig, Till L. et al.
molecules
Article
Magnetic Accumulation of SPIONs under Arterial
Flow Conditions: Effect of Serum and Red Blood Cells
Till L. Hennig, Harald Unterweger, Stefan Lyer, Christoph Alexiou and Iwona Cicha *
Section of Experimental Oncology und Nanomedicine (SEON), ENT-Department, Universitätsklinikum
Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
* Correspondence: Iwona.Cicha@uk-erlangen.de or Iwona.Cicha@yahoo.com; Tel.: +49-9131-8543953
Received: 20 May 2019; Accepted: 14 July 2019; Published: 16 July 2019


Abstract: Magnetic drug targeting utilizes an external magnetic field to target superparamagnetic
iron oxide nanoparticles (SPIONs) and their cargo to the diseased vasculature regions. In the arteries,
the flow conditions affect the behavior of magnetic particles and the efficacy of their accumulation.
In order to estimate the magnetic capture of SPIONs in more physiological-like settings, we previously
established an ex vivo model based on human umbilical cord arteries. The artery model was employed
in our present studies in order to analyze the effects of the blood components on the efficacy of
magnetic targeting, utilizing 2 types of SPIONs with different physicochemical characteristics. In the
presence of freshly isolated human plasma or whole blood, a strong increase in iron content measured
by AES was observed for both particle types along the artery wall, in parallel with clotting activation
due to endogenous thrombin generation in plasma. Subsequent studies therefore utilized SPION
suspensions in serum and washed red blood cells (RBCs) at hematocrit 50%. Interestingly, in contrast
to cell culture medium suspensions, magnetic accumulation of circulating SPION-3 under the external
magnet was achieved in the presence of RBCs. Taken together, our data shows that the presence of
blood components affects, but does not prevent, the magnetic accumulation of circulating SPIONs.
Keywords: SPIONs; magnetic targeting; nanoparticle accumulation; ex vivo flow model; blood cells
1. Introduction
Nanomedicine offers a unique platform for novel drug delivery approaches to the therapy of
cardiovascular diseases (CVD). Thus far however, clinical impact of nanomedicine in diagnosis or
therapy of CVD has been scarce, despite intensive research efforts [1,2]. One reason for this is an
insufficient accumulation of nanoparticles in the diseased arteries [3]. To achieve the required efficacy,
the parenterally-administered particles should have a long circulation half-life and a high margination
rate, and allow enhanced interactions with endothelial cells in the target vasculature. In arterial
circulation, shear stress-activated processes may significantly affect the nanoparticle internalization
by endothelial cells. Moreover, due to the larger size of the vessels, the rheological behavior of blood
cells in the arterial flow differs from that in the microvessels [4–6]. Red blood cell (RBC) accumulation
in the center of the lumen and the formation of rouleaux, creates a cell-free layer at the vessel wall,
which may strongly affect the margination of nano-sized particles [7]. Previous studies showed
that in flowing blood suspensions, platelets [8] and platelet-sized beads with 2.38 µm diameter [9]
strongly accumulate within the cell-free layer near the vessel walls, as compared with the central
region of the flow. According to the mathematical model developed by Lee et al., this is due to
the fact that ellipsoidal microparticles display stronger hydrodynamic margination under flow than
sub-micrometer and nanometer particles [10]. From this model, the minimum equivalent radii for
observing margination under normal hemodynamic conditions (i.e., shear rate of 103/s) with no external
forces would be 7 µm for silica, or 3.5 µm for iron oxide particles. For particles with nanometer
Molecules 2019, 24, 2588; doi:10.3390/molecules24142588 www.mdpi.com/journal/molecules
Molecules 2019, 24, 2588 2 of 16
size-range, the modelled contributions of the inertial and gravitational forces under physiological
conditions are negligibly small, preventing their margination [10]. These mathematical predictions
indicate that, in the absence of external forces, sub-micrometer and nanometer particles of any shape
within the circulation can only oscillate around their trajectory. Passive targeting can thus be used
to deliver nanotherapeutics to the diseased regions, but its efficacy is limited to the vascular beds
where the blood–tissue barrier in horizontal capillaries is compromised. Conjugating nanoparticles
to specific ligands that target endothelial activation markers is considered a useful approach to
enhance the internalization of particles under arterial flow. However a series of comprehensive ex
vivo investigations concerning the endothelial interactions with nano- and microparticles conjugated
with sialyl Lewisa (sLea), a ligand specific to the endothelial selectins, showed that nanoparticles
(100–500 nm) displayed minimal margination towards the endothelial monolayer in human whole
blood flowing in rectangular chambers of varying heights [11,12]. In contrast, a significantly higher
binding of intermediately-sized microspheres (2–5 µm) was detected in this model [11]. Notably,
whereas microparticle attachment to the endothelium was 2 to 4-fold increased under pulsatile blood
flow compared to laminar flow, the margination of nanoparticles was not enhanced, and although
margination of rod-shaped microparticles with high aspect ratios was significantly improved as
compared to spheres of equal volume, the nanorods did not display enhanced margination compared
to that of nanospheres [12]. The authors concluded that both nanorods and nanospheres show no
margination in the presence of RBCs in vitro, confirming the theoretical predictions of Lee et al. [10].
These in vitro and ex vivo results indicate that many types of nanocarriers may not be adequate for
vascular applications in human arteries due to their small size and/or insufficient margination from the
bloodstream. Extensive efforts are therefore focused on identifying efficient targeting approaches that
could enhance the binding of nanoparticles to vascular endothelium at the disease-specific regions,
including medium and large vessels.
One of these approaches, so-called magnetic drug targeting (MDT) utilizes an external magnetic
field to accumulate superparamagnetic iron oxide nanoparticles (SPIONs) and their cargo at the
diseased vasculature regions [13]. The magnetic properties of SPIONs allow their visualization by
magnetic resonance imaging, but also the remote control of their accumulation in vivo. However,
in contrast to their broad utility as imaging agents [14–18], relatively few reports addressed the use
of SPIONs for cardiovascular drug delivery thus far [19–21]. In spite of the fact that a number of
papers were previously published concerning magnetic targeting of SPIONs under flow conditions,
the majority of studies [22–25] addressed this process either in flow models that do not reflect
arterial wall geometry (glass or plastic tubes) or in cancer models, where due to increased endothelial
permeability and EPR effect, the leakage of magnetofluids in the tissue is easily achieved. Magnetic
capture of nanoparticles under flow conditions characteristic for larger vessels may be more difficult
to achieve, as the force exerted by the magnetic field must overcome the hydrodynamic (drag) force
and the shear effects generated by the flowing blood cells. Apart from the specific nanoparticle
characteristics [26], the magnetic field gradients and the flow dynamics thus determine the behavior
of magnetic particles in circulation and the efficacy of their accumulation. In order to estimate the
magnetic capture of SPIONs in more physiological-like settings, we previously established an ex vivo
model based on the human umbilical cord arteries [27]. Using this model, we investigated the magnetic
targeting of SPIONs suspended in cell culture media under various external magnetic field gradients
and flow conditions, showing that accumulation of some types of SPIONs at the arterial wall is
achievable under the guidance of a sufficiently strong external magnet. As only cell culture media were
used in the previous study, among the unanswered questions are the effects of blood components (both
at the cellular and protein level) on nanoparticle behavior under arterial flow conditions. It is extremely
difficult to estimate these effects based on mathematical simulations, and thus far comprehensive
standardized studies are missing that would investigate the efficacy of particle accumulation under
external magnetic field in the presence of blood components. To address these questions, the artery
model was employed in our present studies in order to analyze the effects of the blood components
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on the efficacy of magnetic targeting, utilizing SPIONs with different physicochemical characteristics.
The novelty of this work involves the use of human tissue model to investigate the possibility and the
conditions required for capture of circulating SPIONs under uninterrupted arterial flow conditions in
the presence of blood components.
2. Results
To answer the need for an easy to handle basic research model system for MDT investigations
under arterial flow conditions, we previously developed and reported an ex vivo model based on
the branch-free human umbilical cord arteries (Figure A1). Originally, three types of SPIONs were
considered, including lauric acid-coated iron oxide nanoparticles synthesized according to Khalafalla
et al. [28] (SPION-1, with 126 nm hydrodynamic diameter and ζ-potential of –34.6 mV), as well as
SPION-2 with improved lauric acid/albumin coating and SPION-3 with crosslinked dextran coating.
In our present study, we focused on investigations of SPION-2 and SPION-3, due to the fact that
SPION-1 showed limited stability in human blood and poor batch to batch reproducibility. For the sake
of consistency, we kept the original terminology of the tested SPIONs. The detailed characterization of
these particles was reported before and is summarized in Supplementary Table S1 and Supplementary
Figure S1.
2.1. Magnetic Capture Efficacy of SPIONs in the Presence of Plasma and Whole Blood
In our present study, the ex vivo artery model was used to evaluate the magnetic accumulation of
SPIONs with different coatings and physicochemical properties in the presence of blood components.
The following particles were used: SPION-2 with lauric acid/albumin shell (71 nm hydrodynamic
diameter and ζ-potential of −18.3 mV), and SPION-3 with dextran shell (74 nm hydrodynamic diameter
and ζ-potential of −3.8 mV). Both these particle types have been shown to be stable in whole blood
(Supplementary Figure S2) [29,30]. We never observed any agglomeration in SPION-2 or SPION-3
samples in the presence of serum proteins, nor the induction of plasma coagulation (Supplementary
Figure S3). Due to their good biocompatibility, these SPIONs are currently used in proof-of-feasibility
animal studies for different clinical applications [21,29].
In the first set of experiments, we prepared the respective SPION suspensions using freshly
isolated human plasma or whole blood. In plasma, a strong peak in SPION-2 accumulation under the
magnet, slightly shifted towards segment −1 was observed (Figure 1a). The iron content measurements
in SPION-3 samples also demonstrated a presence of a peak around segments 0 and +1, but there was
a large variability between single experiments (Figure 1b). There were no major differences between
the SPION-2 and SPION-3 in the absolute iron concentrations (peak levels between 1000–2000 ng
Fe/segment).
When particles were suspended in freshly isolated citrated human blood, an overall strong
increase in iron content along the artery wall was measured, which may be related to partial hemolysis
of the RBCs during the multiple circulation rounds within the flow system. A mild peak under the
magnet (segment 0) was observed for SPION-2 (Figure 2a). Interestingly, a stronger iron accumulation
and a more pronounced peak were observed in SPION-3 samples (Figure 2b). Figure 3 shows the
representative histological images of the respective segments 0 under the magnetic tip, stained with
Prussian blue.
It must be noted, however, that during perfusion of SPION suspensions either in plasma or
in whole blood through the umbilical arteries from different donors, a strong increase in clotting
was detected (Figure 4). This efect was not observed in SPION suspensions before the perfusion
through the artery model, or in our previous in vitro studies (Supplementary Figures S2 and S3), so
the pro-coagulatory state was clearly induced by the activation of endogenous blood thrombin upon
contact with arterial vessel wall.
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indicates the direction of flow. Shown is iron concentration of respective segments (median with 75th 
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magnet) are indicated by dashed line. * P < 0.05 versus segment 0; trend P values are indicated.
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Figure 2. Magnetic targeting of circulating SPION-2 and SPION-3 suspended in whole blood (WB).
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versus segment 0; trend P values are indicated.
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Figure 4. Representative macroscopic images of the artery models after the experiments with (a) plasma
and (b) whole blood. Lower panel shows clots washed out after the experiments.
2.2. Magnetic Capture of SPIONs in the Presence of Serum and Washed RBC Suspensions
To overcome the problem of clotting, human serum (cell-free part of blood devoid of clotting
factors such as fibrinogen) or washed RBC resuspended in PBS to 50% hematocrit were used in
the subsequent set of experiments. Under these conditions, no clotting activation was observed in
the perfused samples, either controls or nanoparticle-containing suspensions. Compared to plasma
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samples, the SPION suspensions in serum showed a very week margination and only mild peaks were
observed for both types of SPIONs around segments 0 and −1 (Figure 5). The absolute values of iron
measured with AES were very low, around 150–220 ng Fe/segment in the peak regions.
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Figure 5. Magnetic targeting of circulating SPION-2 and SPION-3 suspended in serum. (a) SPION-2 and
(b) SPION-3 suspensions at 30µg Fe/mL were circulated in the model for 30 min under external magnetic
force positioned at segment 0. Arrow indicates the direction of flow. Shown is iron concentration of
respective segments (median with 75th and 25th percentile of n = 5 experiments). Average control
values (SPIONs suspensions without magnet) are indicated by dashed line. ** P < 0.01, * P < 0.05,
versus segment 0; ‡ P = 0.066 versus segment −1; trend P values are indicated.
When SPIONs were perfused through the artery model in RBC suspensions at 50% Ht, overall
much less RBC accumulation in the artery was observed (Figure A2) as compared with whole blood.
In comparison to serum, increased accumulation of iron was observed in arterial tissue. In SPION-2
samples, a shift of the peak of accumulated iron towards distal segments (0, +1, +2) was measured
(Figure 6a). Interestingly, although in our previous study, we did not observe an accumulation of
circulating SPION-3 suspended in cell culture media under the tip of the magnet, in the presence of
RBCs, SPION-3 were successfully accumulated at the same value of magnetic field gradient (Figure 6b).
The magnetic capture was sufficiently strong for clear iron visualization using histochemical staining
(Figure 7).
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(a) SPION-2 and (b) SPION-3 suspensions at 30 µg Fe/mL were circulated in the model for 30 min
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versus segment 0; trend P values are indicated.
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3. Discussion
In order to design safe intravascular drug delivery nanosystems, their basic physicochemical
characteristics and biological effects on the vascular and blood cells must be investigated [31,32].
Furthermore, the effects of hemodynamic forces on nanoparticle behavior in circulation and their
adhesion to the endothelium must be considered [26]. For the delivery of nanocarriers to the vascular
wall, passive and active targeting have been used. Passive targeting exploits the enhanced endothelial
permeability in inflammatory diseases and cancer, which facilitates the extravasation of nano-sized
particles [33]. Nanoparticles that prolong the circulation half-life of the carried drugs are therefore
expected to increase the payload of drugs reaching the target-site. However, despite the presence
of leaky vessels in tumors, the efficacy of drugs and passively-targeted drug carriers applied via
intravenous route is often insufficient for a meaningful clinical improvement [34]. For this reason,
nanoparticulate carriers that can be used for targeted drug delivery to the vascular wall constitute an
attractive alternative. The active targeting of nanoparticles can be achieved by grafting the surface
or the shell of the nanocarriers with specific ligands or antibodies to molecules expressed on the
endothelium. However, this approach does not necessarily improve efficacy, as few nano-sized
particles are expected to marginate towards human artery walls due to their small size and the specific
hemodynamic conditions. MDT thus seems to represent a promising strategy of drug delivery, which
results in increased drug payloads in the target tissue, at the same time reducing their systemic dose
and toxicity [22,35]. Using this technique, we have recently demonstrated the possibility of SPION
accumulation in abdominal aorta of living rabbits [21].
Our former study highlighted the importance of nanoparticle coating on the magnetic accumulation
under arterial flow. When nanoparticles were suspended in low-serum endothelial cell culture medium,
SPION-1 with lauric acid shell had the largest capacity to accumulate at the specific artery segment.
SPION-2 (lauric acid/albumin-coated) were also successfully targeted, although the iron content was
smaller than for SPION-1. In that study, we did not achieve magnetic accumulation of dextran-coated
SPION-3 suspended in cell culture medium, likely due to the steric repulsion resulting from their
specific surface chemistry [36], which may reduce the dipole–dipole interactions between the particles.
Furthermore, the use of cell culture media instead of blood or human plasma for preparing the
circulating SPION suspensions was a major limitation that could greatly impact the magnetic capture
efficacy. Our present study was thus dedicated to investigating the effects of blood components on the
accumulation of SPIONs under an external magnetic field.
In the first attempts, we prepared the respective SPION suspensions using freshly isolated human
plasma or whole blood. For SPION-2 samples in plasma, a strong peak in iron concentration shifted
towards segment −1 was observed, whereas a milder peak with stronger variability between samples
was noted for SPION-3. In the whole blood samples, a strong increase in iron content measured by
AES was observed for both particle types, which may be related to partial hemolysis of the RBCs
during the multiple circulation rounds within the flow system, but also to the accumulation of RBC
aggregates in the artery despite stringent washing. Perfusion of plasma and whole blood suspensions
through the isolated umbilical artery from a different donor resulted in a strong activation of clotting
factors. This was an unexpected finding, which can however be explained by an endogenous thrombin
generation in plasma, that occurs e.g., by contact with cells expressing tissue factor (TF). Thrombin is the
central coagulation protease that activates clotting proteins, triggers platelet aggregation, and converts
fibrinogen to fibrin [37]. Upon the contact of flowing exogenous plasma with arterial endothelial
cells expressing TF, a pro-coagulative effect is induced, whereby fibrinogen contained in plasma is
converted into a fibrin mesh that can affect the flow and/or entrap the flowing particles (Figure A3).
This pro-coagulative effect has been previously observed in transfusion medicine, where RBC-derived
microparticles isolated from blood units, or graft products for peripheral blood stem cell transplantation,
were reported to initiate and propagate thrombin generation [38,39]. The use of RBCs stored for
more than 28 days has been associated with an increased incidence of deep vein thrombosis in the
recipient, most likely due to coagulation activation [40,41]. It must also be noted that after blood
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sample centrifugation, remnant platelets may remain suspended in plasma and become activated by
thrombin. Our finding is of technical importance for the investigations involving human plasma and
whole blood in the artery models mimicking in vivo situation. The clotting effect was not reported in
the previously published studies with whole blood circulating in plastic chambers [11,12] and was not
observed in our samples prior to their perfusion through the artery.
To overcome this problem, in the second set of experiments, we have therefore used human serum
(cell-free part of blood devoid of clotting factors such as fibrinogen) or washed RBC resuspended in
PBS to 50% Ht. Under these conditions, no clotting activation was observed in the perfused samples,
either controls or nanoparticle-containing suspensions. In the serum samples, the accumulation of
particles was low as compared with plasma. Slight, but not significant, peaks in iron concentration
were observed around the artery segments from −1 to +1. The most notable finding refers to the
results obtained with SPION-3 suspended in RBC at Ht of 50%. In our previous study, using the
particle suspensions in cell culture media, we did not achieve an accumulation of circulating SPION-3
under the tip of the magnet. Here, in the presence of RBCs, SPION-3 were successfully accumulated
in the target region. This finding warrants further studies, both in vitro and numerical simulations,
concerning the potential interactions of SPION-3 with flowing RBCs. In this context, former in silico
mathematical simulations based on the tubular vessel models predicted that magnetic accumulation
of nanoparticles against the hydrodynamic drag force is not possible [42]. However, more recent
simulations and experiments suggest that in situ reversible aggregates which are formed by interaction
of SPIONs’ magnetic dipoles greatly contribute to magnetic accumulation of SPIONs [43–45]. Thus far,
we have little data on how the SPION-3 coating is affected in the presence of blood proteins. In our
former in vitro investigations, we did not detect the formation of hard protein corona on SPION-3,
likely due to the presence of stable crosslinked dextran coating, which is nearly neutral. Slightly more
protein adsorption was observed on SPION-2 (unpublished observations). However, it cannot be
excluded that a lose protein corona forming on the SPION-3 may enhance the dipole-dipole interactions
between the particles. Furthermore, the hemodynamic effects of blood-borne cells must be taken into
account. In the arteries, characterized by large diameter and increased shear stress, the multi-file
flow of RBC creates a cell-free layer at the vessel wall. As a consequence, two scenarios are possible:
the particles may become pushed out of the lumen center by the forming rouleaux, thus increasing
their margination, or they may be captured among the vortex-like flow among RBCs in the center of
the lumen. Thus far, multi-file flow was assumed to improve margination of microparticles, and not
nanoparticles, but these investigations were done in the absence of external forces. SPION-3, having a
high aspect ratio and irregular branched shape may be prone to escape from the central column of
RBC flow, if an external magnetic force of sufficient strength is present. Further investigations will be
necessary to clarify the mechanisms of margination and magnetic accumulation of SPION-3 under
arterial flow conditions.
Our study has several limitations. One of them is related to a relatively small sample size, which
was limited by the availability of human umbilical arteries and resulted in low statistical power. As
also explained in the methods below, with some of the samples, we could not complete the experiments,
due to the variations in material quality, or postpartum blood collection procedures. Despite this
fact, 64 magnetic targeting experiments were successfully performed, whereby 5 independent artery
samples from different donors used for iron content measurement and 3 for histological evaluation, for
each SPION type and each experimental condition. Another limitation of our model is that the short
duration of the flow experiment does not allow reaching conclusions about cellular uptake of SPIONs.
The 30 min experiment, after which the arterial tissue is fixed, is too short to detect particle uptake in
specific cell types. We can solely observe whether the particles have tendency to accumulate at the
lumen surface, or whether they penetrate vessel wall during this period of time.
Due to a major problem arising from inadequate doses of the approved nanomedicinal products
reaching the diseased tissues [34], improving the targeting efficacy using external magnetic field and
drug-loaded SPIONs is a very important first step in local drug delivery [46]. Our studies aim to
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evaluate the possibility of improved SPION accumulation and determine the best conditions for the
two model particles. The need to assess the subsequent particle biodistribution, tissue kinetics and
clearance, as well as immune responses is unquestionable and must be addressed in the future, but
this type of analyses can only be done in a living organism, using appropriate animal models.
4. Materials and Methods
4.1. Materials
Lauric acid, epichlorohydrin, iron (III) chloride hexahydrate and dextran T40 (Mw = 40 kDa)
were from Sigma Aldrich (Munich, Germany). Bovine serum albumin (BSA) and iron (II) chloride
tetrahydrate were from Merck (Darmstadt, Germany). NaOH, HCl (25%), NH3 (25%), nitric acid
(65%w/w), potassium ferrocyanide, and agarose were from Roth (Karlsruhe, Germany). All compounds
used were of pharmaceutical (Ph. Eur) or highly pure (>99%) grade and were used without any further
purification. Ringer solution was obtained from Fresenius Kabi (Bad Homburg, Germany).
4.2. Nanoparticle Synthesis and Characterization
The tested types of SPIONs were synthesized at the Section of Experimental Oncology and
Nanomedicine, University Hospital Erlangen [27].
SPION-2: Lauric acid/BSA-coated iron oxide nanoparticles were synthesized by co-precipitation,
subsequent in situ coating with lauric acid, and formation of an artificial albumin corona as described
by Zaloga et al. [47]. Briefly, Fe (II) and Fe (III) salts at a defined molar ratio (Fe3+/Fe2+ = 2) were
dissolved in water and stirred at 80 ◦C under argon atmosphere, followed by addition of NH3 solution
(25%). The solution was heated to 90 ◦C and lauric acid, dissolved in acetone, was added. The brownish
suspension was left to homogenate for 30 min at 90 ◦C. The suspension was then dialyzed multiple
times against ultrapure water. Subsequently, SPIONs were stabilized by incubation with a freshly
prepared 20% BSA solution, purified by centrifugal ultrafiltration (molecular weight cut-off 100 kDa),
and sterilized by filtration through a 0.22 µm filter.
SPION-3: For the preparation of dextran-coated iron oxide nanoparticles, the synthesis method
described by Unterweger et al. was used [48]. Briefly, Fe (II) and Fe (III) salts in molar ratios (Fe3+/Fe2+
= 2) as well as dextran T40 were dissolved in water. After cooling to 4 ◦C under continuous stirring
and argon atmosphere, ice-cold 25% NH3 was added. After 5 min, the reaction mixture was heated
and kept at 75 ◦C for a further 40 min, followed by cooling to RT and dialysis (molecular weight cut-off
8 kDa). The mixture was then cleared from excess dextran and concentrated using ultrafiltration
(molecular weight cut-off 100 kDa). To stabilize the dextran coating, crosslinking was performed by
adding epichlorohydrine dropwise to the nanoparticle suspension after alkalization with NaOH under
vigorous stirring. The solution was then dialyzed against water, concentrated by ultrafiltration and
sterile filtered through 0.22 µm membrane.
The extensive physicochemical characterization of these particles was reported in the previous
publications [49,50].
4.3. Blood Collection
Peripheral venous blood from healthy donors was drawn into sodium citrate Monovette (106 mM,
1:10 v/v), or serum Monovette (Sarstedt, Germany). Citrated blood was divided into aliquots and used
for flow experiment, or centrifuged at 190 g for 10 min to obtain RBCs suspension and plasma. RBCs
were washed twice in PBS to remove the traces of plasma and resuspended in PBS at Ht of 50%. Serum
was obtained after clotting of blood by centrifugation at 1500 g for 10 min and used for the experiments
immediately. The remaining volumes of serum were stored at −80 ◦C for the future use. The use of
human blood was approved by the local ethics committee at the University Hospital Erlangen (review
No. 4449).
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4.4. Umbilical Artery Preparation
Human umbilical arteries were isolated from freshly collected umbilical cords (kindly provided by
Prof. Beckmann, Dept. of Gynecology, Universitätsklinikum Erlangen). Within 1–4 days post-partum,
the cords were used for isolation of primary HUVECs from umbilical vein. After HUVECs isolation was
completed, the umbilical arteries were prepared from the cords, washed and cut in 13 cm fragments,
used for the flow experiment as reported previously [27]. The study was conducted according to the
Declaration of Helsinki and the relevant national guidelines. The use of human material was approved
by the local ethics committee at the University Hospital Erlangen (review No. 4449). Written informed
consent was obtained from donors.
4.5. Flow Experiments
At each end of a 13 cm long artery fragment, plastic Luer connectors (Novodirect, Kehl, Germany)
were fixed with surgical thread. After rinsing multiple times with Ringer solution to remove the
remaining blood clots, artery fragments were placed in a plastic container and subsequently filled
with pre-warmed endothelial cell culture medium to prevent the lumen collapse. Arteries were then
embedded in agarose gel and connected to the peristaltic pump (model ISM 915, Ismatec, Wertheim,
Germany) and SPION reservoir using Ismaprene tubes (Ismatec). In this set-up, samples of human
plasma, serum, whole blood and washed red blood cells (50% Hct) containing SPIONs (30 µg/mL) were
perfused through the artery with or without an external magnetic force for 30 min, at the flow rate of
4.8 mL/min (corresponding to the shear stress of 5 dyne/cm2). The selected concentration of circulating
SPIONs (30 µg/mL) was comparable to the maximal systemic dose of iron oxide-based contrast agent
ferumoxtran (2.6 mg/kg body weight, corresponding to 33 µg/mL blood in humans). In the experiments
with magnetic field gradient (Siemens electromagnet, Siemens AG Erlangen, Germany), the magnetic
field gradient at the tip of the pole shoe was set for 72 T/m, which corresponded to about 40 T/m field
gradient at the center of artery lumen. The tip of the magnet was positioned directly on top of the
agarose gel surface, in a 5 mm distance from the wall of embedded artery. As controls, SPIONs without
external magnetic field gradient were used. After the experiment, the arteries were rinsed with Ringer
solution for 2 min, or for 15 min in the case of RBC-containing suspensions. Subsequently, the models
were disconnected from the pump and arteries were cut into segments of 1 cm length, numbered (−5, .
. . ,0, . . . ,+5) from in-flow to out-flow, followed by additional rinsing of single sections with Ringer
solution. Due to the variations in material quality, postpartum blood collection procedures and other
independent factors, some artery samples were not suitable for performing the experiment, especially
if the artery was punctured. In total, we collected above 80 artery samples for the study, and with
64 of them we successfully completed the magnetic targeting experiments. For each SPION type
and each experimental condition, 5 independent artery samples from different donors were used for
subsequent iron content measurement and 3 for histological evaluation. Additionally, n = 2–4 samples
were used as negative controls (with SPIONs in respective media, without magnet). Due to the fact
that the inflow and outflow regions (−5, −4 and +4, +5) are prone to a processing damage during the
placement of connectors, which may lead to an aberrant accumulation of circulating SPIONs at the
injured region [27], only the regions from −3 to +3, which experience uniform flow conditions, were
considered in the analyses.
4.6. Iron Content Measurement with AES
The tissue iron concentration was quantified with microwave plasma atomic emission spectroscopy
(MP-AES, 4200 device, Agilent, Waldbronn, Germany). Following the flow experiment, the rinsed
tissue segments were dried for 2 h at 90 ◦C, dissolved in 100 µL of 65% nitric acid for 10 min at 95 ◦C
and 600 rpm using a thermomixer. After addition of 900 µL of water, the emission spectrum of the
samples was analyzed and compared to the standard curves. Tissue iron concentration values were
given as ng Fe per artery segment.
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4.7. Tissue Iron Content by Histology
The tissue segments were stained with Prussian blue to assess the uptake of circulating SPIONs.
Briefly, the artery segments were placed in embedding cassettes, fixed in 4% formaldehyde solution
(Roth) in PBS buffer for 2 days. Afterwards, samples were dehydrated in an ascending isopropanol
sequence and finally embedded in paraffin. Blocks were then cut using the microtome and the
paraffin-embedded serial sections of 4-µm-thickness were dewaxed in xylene, rehydrated in ethanol,
and immersed in 1:1 solution of hydrochloric acid (2%) and potassium ferrocyanide (2%) for 30 min at
RT. Nuclei of the cells were counterstained with eosin, followed by rinsing with distilled water. As a
mounting medium, Mowiol (Sigma-Aldrich) was added to extend staining durability. Images were
taken using Axio Observer.Z1 microscope (Zeiss, Jena, Germany).
4.8. Statistics
The differences in magnetic accumulation of SPIONs between the different segments of the
artery model were calculated after performing a normality test (Shapiro–Wilk), using t-test in samples
that passed the normality test and non-parametric Mann–Whitney U-test in those, which failed the
normality test. Data were expressed as median with 75th and 25th percentile, unless stated otherwise.
P < 0.05 was considered statistically significant.
5. Conclusions
In conclusion, our studies identified the clotting effect induced by perfusion of plasma and whole
blood in the human artery model as a potential confounding factor. The presence of serum did not
greatly affect the magnetic capture of SPION-2, while in the presence of RBCs, the iron accumulation
was increased, with a peak shifted to distal artery region. The presence and rheological behavior of
RBCs in the arterial flow improved the capturing efficacy of SPION-3. Further investigations and
numerical simulations will be necessary to clarify the mechanisms of margination and accumulation of
SPION-3 under arterial flow conditions. This knowledge will be essential to ensure a broader and
more efficient implementation of these particles in clinical practice in the future.
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